Is Camurus (OM:CAMX) Still Undervalued On Its FDA CAM2029 Milestone? Simply Wall St 08:18 Wed, 29 Jul
FDA Accepts Camurus’ Resubmitted NDA for CAM2029 in Acromegaly Endocrinology Advisor 14:36 Tue, 21 Jul
Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA PR Newswire (Press Release) 06:26 Fri, 17 Jul
